Hims & Hers Health, Inc.
Here’s whether Hims & Hers Health, Inc. (HIMS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+2.38% over 10 days); RSI 55 — healthy momentum range; 3-month momentum positive (+18.2%). Concerns: trading below the 200-day MA (long-term downtrend); weak 1-year return of -50.4%; declining volume on rally — weak conviction (0.79x 30d avg). Currently 62.8% off its 52-week high. Score: +0/7.
HIMS is trading below its 200-day MA ($33.98) — a key warning sign the longer-term trend is under pressure. An RSI of 55.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -50.4% compares to +24.4% for SPY (trailed the market by 74.7%). The current 62.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.